Periodic Reporting for period 1 - HYPERQTOTAL (“Diagnosis of Ischemic Heart Disease by means of innovative and highly accurate high frequency QRS electrocardiogram analysis”)
Reporting period: 2016-02-01 to 2016-04-30
We have conducted this feasibility analysis by contacting potential clients, partners and hospitals who could assist us in the execution of the clinical validation study that is foreseen in a consecutive Phase 2 project. Central issue in this feasibility analysis was the question how HyperQTotal could be commercially launched in the most optimal manner, considering the CAD diagnostics market and purchasing power by its stakeholders. Moreover, we have considered several business and revenue models.
An estimation of the cost-effectiveness of implementing HyperQTotal for diagnosis of CAD demonstrated a potential reduction of 13% in unnecessary cardiac imaging tests and of 4% in superfluous coronary angiography procedures. Additionally, indirect costs savings related to better prognosis should be considered as well as the social impact on patients and their families.
HyperQTotal can be implemented on half of the existing ECG-hardware available (about 60% of all currently used computer-based systems) and only involves software for collecting and analysing the HF-data of the ECG and converting this data into useful information for any cardiologist, who will only need short training in interpretation of the HF-QRS information. It will be offered primarily to cardiologists and hospitals on a Pay-per-Test basis by providing it as a cloud service.
HyperQTotal can be implemented on half of the existing hardware being software for collecting and analysing HF-data of an ECG and converting it into useful information for any cardiologist, who will only need brief training in interpreting HF-QRS data. It will be offered primarily to cardiologists and hospitals on a Pay-per-Test basis.
We have prepared a work plan for future work, which includes the development of HyperQTotal´s new features and a clinical validation study to prove the superiority of HyperQTotal over its precessor, HyperQ, and regular ECG software.
After 5 years commercialization, we aim to have HyperQtotal operating 2 Million stress-ECG tests per year, which would create around €48 Million of revenues. This success would create up to 30 new positions in BSP Medical.
Our estimations forecast that improved sensitivity of HyperQTotal entails a 4% reduction in the incidence of acute coronary events, 5% reduction in heart failure and 5% reduction in mortality among CHD patients. Moreover, the potential immediate annual savings amount to €400 Million. We expect that 25% of these savings can be achieved in Europe, 40% in North America and 35% in the rest of the world, predominantly in Asia.
Future application of HyperQTotal also comprises portable ECG-systems and wearables for individuals.